Antihyperglycaemic treatment of type 2 diabetes: results from a national diabetes register

Diabetes and Metabolism

Volumn 33, Issue 4, 2007, Pages 269-276

  Eliasson, B ^a   Eeg Olofsson, K ^a   Cederholm, J ^b   Nilsson, P M ^c   Gudbjornsdottir S ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Diabetes mellitus; Epidemiology; Hypertension; Hypoglycaemic agents; Insulin; National register

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; LIPID;

ADULT; AGED; ARTICLE; BONE DENSITY; DISEASE DURATION; FEMALE; GLYCEMIC CONTROL; HEALTH SURVEY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; REGISTER; RISK FACTOR; SMOKING; SWEDEN; BLOOD; BODY MASS; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DIABETIC ANGIOPATHY; GLUCOSE BLOOD LEVEL; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; REGISTRIES; SWEDEN;

EID: 34548703609     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2007.02.003     Document Type: Article

References (27)

1. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
2. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348 (2003) 383-393
3. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287 (2002) 360-372
4. Dormandy J.A., Charbonnel B., Eckland D.J.A., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in MacroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
5. Standards of medical care in diabetes. Diabetes Care 27 Suppl 1 (2004) S15-S35
6. De Backer G., Ambrosioni E., Borch-Johnsen K., Brotons C., Cifkova R., Dallongeville J., et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur. Heart J. 24 (2003) 1601-1610
7. Eliasson B., Cederholm J., Nilsson P., Gudbjörnsdottir S., and for the Steering Committee of the Swedish National Diabetes Register. The gap between guidelines and reality: type 2 diabetes in a National Diabetes Register 1996-2003. Diabet. Med. 22 (2005) 1420-1426
8. Saydah S.H., Fradkin J., and Cowie C.C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291 (2004) 335-342
9. Nilsson P.M., Gudbjornsdottir S., Eliasson B., and Cederholm J. Hypertension in diabetes: trends in clinical control in repeated large-scale national surveys from Sweden. J. Hum. Hypertens. 17 (2003) 37-44
10. Gudbjornsdottir S., Cederholm J., Nilsson P.M., and Eliasson B. The National Diabetes Register in Sweden: an implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Diabetes Care 26 (2003) 1270-1276
11. Diabetes care and research in Europe: the Saint Vincent declaration. Diabet. Med. 7 (1990) 360
12. Hoelzel W., Weykamp C., Jeppsson J.O., Miedema K., Barr J.R., Goodall I., et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin. Chem. 50 (2004) 166-174
13. Stevens R.J., Kothari V., Adler A.I., Stratton I.M., Holman R.R., and on behalf of the United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Multimedia adjunct. Clin. Sci. 101 (2001) 671-679
14. Kothari V., Stevens R.J., Adler A.I., Stratton I.M., Manley S.E., Nel H.A., et al., for the UK Prospective Diabetes Study Group. UKPDS 60. Risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study Risk Engine. Stroke 33 (2002) 1776-1781
15. DeWitt D.E., and Hirsch I.B. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 289 (2003) 2254-2264
16. Wright A., Burden A.C., Paisey R.B., Cull C.A., and Holman R.R. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 25 (2002) 330-336
17. Yki-Jarvinen H., Ryysy L., Nikkila K., Tulokas T., Vanamo R., and Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann. Intern. Med. 130 (1999) 389-396
18. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998) 837-853
19. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998) 854-865
20. Pratley R.E., and Weyer C. The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia 44 (2001) 929-945
21. Wingard D.L., and Barrett-Conner E. Heart disease and diabetes. Diabetes in America. 2nd ed. National Diabetes Data Group, Ed (1995), Washington, DC, US, Govt. Printing Office 429-448 (NIH publ. no. 95-1468)
22. Pedula K.L., Hillier T.A., Brown J.B., and Lydick E. Macrovascular disease: progressive macrovascular disease in a population with type 2 diabetes. Diabetologia 42 (1999) A176 (Abstract)
23. Must A., Spadano J., Coakley E.H., Field A.E., Colditz G., and Dietz W.H. The disease burden associated with overweight and obesity. JAMA 282 (1999) 1523-1529
24. Hillier T.A., and Pedula K.L. Characteristics of an adult population with newly diagnosed type 2 diabetes. Diabetes Care 24 (2001) 1522-1527
25. Wroblewski M., Gottsater A., Lindgarde F., Fernlund P., and Sundkvist G. Gender, autoantibodies, and obesity in newly diagnosed diabetic patients aged 40-75 years. Diabetes Care 21 (1998) 250-255
26. Berger B., Stenstrom G., and Sundkvist G. Incidence, prevalence, and mortality of diabetes in a large population. A report from the Skaraborg Diabetes Registry. Diabetes Care 22 (1999) 773-778
27. Berger B., Stenström G., Chang Y.-F., and Sundkvist G. The prevalence of diabetes in a Swedish population of 280,411 inhabitants. A report from the Skaraborg Diabetes Registry. Diabetes Care 21 (1998) 546-548